Skip to main navigation Skip to search Skip to main content

Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia

Elisabet Lloveras, Isabel Granada, Lurdes Zamora, Blanca Espinet, Lourdes Florensa, Carles Besses, Marisol Xandri, Maria Encarnación Pérez-Vila, Fuensanta Millà, Soledad Woessner, Francesc Solé

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We report cytogenetic results in a series of 60 patients affected with multiple myeloma (MM) and plasma cell leukemia (PCL) and compare the results with those previously reported. In our series, a total of 41% of MM patients and 71% of PCL patients displayed chromosome abnormalities. To evaluate the clinical value of monosomy 18, we obtained fluorescence in situ hybridization results (using centromeric probe for chromosome 18) of 22 MM patients who displayed a normal karyotype. Monosomy 18 was present in 3 of 22 patients (14%). Using conventional cytogenetics, we detected monosomy 18 in one patient affected with PCL. Two of four cases with monosomy 18 followed an aggressive course, with overall survival of 1 and 9 months. The remaining two are in follow-up and remain stable. The association of monosomy 18 with IgA subtype predominance and poor prognosis was not observed in this series of MMs and PCLs. Although these results do not confirm our previous hypothesis, further observations of this group of patients (with monosomy 18) regarding malignant transformation is warranted. © 2004 Elsevier Inc. All rights reserved.
Original languageEnglish
Pages (from-to)71-76
JournalCancer Genetics and Cytogenetics
Volume148
Issue number1
DOIs
Publication statusPublished - 1 Jan 2004

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Cytogenetic and fluorescence in situ hybridization studies in 60 patients with multiple myeloma and plasma cell leukemia'. Together they form a unique fingerprint.

Cite this